LKT Labs

Biochemicals for Life Science Research

Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $127.60 In stock
100 mg $317.50 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7
Purity

≥97%
Formula

C26H46N2O
Formula Wt.

402.66
IUPAC Name

C26H46N2O
Synonym

Bebuxine, Cyclovirobuxine
Melting Point

219-224°C
Appearance

White crystal

Shipping and Storage

Store Temp

4°C
Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF
Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • F1607

    Febuxostat

    Xanthine oxidase inhibitor.

    ≥98%
  • A1016

    S-Acetyl-L-glutathione

    Alters intracellular glutathione levels.

    ≥98%
  • P698583

    Prostaglandin E2

    principal metabolic product of COX-2

    ≥98%
  • T1677

    Tetracycline

    Polyketide; protein translation inhibitor, mamm...

    ≥90%
  • D3372

    Disodium Cycloheptylaminomethylene Diphosphate

    Bisphosphonate; squalene synthase inhibitor.

    ≥98%
  • D1874

    Desvenlafaxine Succinate Hydrate

    Venlafaxine metabolite; SERT and NET inhibitor....

    ≥99%
  • G4532

    Gliclazide

    Sulfonylurea; SUR1 antagonist.

    ≥98%
  • G7240

    GSK-2830371

    Wip1 inhibitor.

    ≥98%
  • D1759

    Deoxynivalenol

    Trichothecene mycotoxin produced by Fusarium.

    ≥98%, TLC
  • S8009

    Substance P (7-11)

    Endogenous tachykinin peptide, involved in infl...

    ≥95%
  • E0073

    Ebselen

    Synthetic glutathione peroxidase mimetic; yeast...

    ≥99%
  • Q8135

    Quinestrol

    Synthetic steroid hormone, estrogen analog, use...

    ≥98%
  • P4780

    Plumbagin

    Naphthoquinone found in Plumbago.

    ≥98%
  • T9970

    Tyrphostin AG1295

    PDGFR inhibitor.

    ≥98%
  • E0929

    Echinacoside

    Phenylethanoid glycoside found in Echinacea.

    ≥98%
  • T2402

    TG100-115

    p110δ and p110γ PI3K inhibitor.

    ≥98%
  • B3472

    4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline

    Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FG...

    ≥98%
  • P2516

    S-(N-Phenylbutylthiocarbamoyl)-L-cysteine

    Cysteine-ITC conjugate, antioxidant.

    ≥98%
  • I8618

    Ivermectin

    Avermectin; glu-gated Cl- channel activator, Gl...

    ≥95%
  • E5241

    Met-Enkephalin

    Endogenous opioid peptide; δOR and μOR agonis...

    ≥95%